SIGA
BEARISH
$4.76
Live
SIGA Technologies, Inc. · NASDAQ
$4.29
52W Range
$9.62
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 19, 2026
Market cap
$341.03M
P/E
14.88
ROE
11.2%
Profit margin
24.6%
Debt/Equity
0.0
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
SIGA presents a stark contrast between a pristine balance sheet and a collapsing operational core, evidenced by a Piotroski F-Score of 4/9 (Stable). While the company maintains zero debt and an exceptional current ratio of 11.83, the YoY revenue decline of -95.30% and an operating margin of -250.38% indicate a severe crisis in business continuity. The current price of $4.76 trades at a premium to both the Graham Number ($4.47) and the Intrinsic Value ($2.24), suggesting the stock is overvalued relative to its fundamentals. Technical trends are fully bearish, and the earnings track record shows a consistent failure to meet analyst expectations.
Key Strengths
Zero debt (Debt/Equity: 0.00)
Extremely high liquidity (Current Ratio: 11.83)
Strong gross margins (47.49%)
Positive net profit margin (24.62%) likely driven by non-operating items
Low Forward P/E (3.24) suggesting potential earnings recovery
Key Risks
Catastrophic revenue collapse (-95.30% YoY)
Severe operating losses (Operating Margin: -250.38%)
Consistent earnings misses (0/4 beats in last 4 quarters)
Strongly bearish technical trend (0/100)
Significant gap between current price and intrinsic value ($2.24)
AI Fair Value Estimate
Based on comprehensive analysis
$3.35
-29.6% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
30
Weak
45
10
20
75
0
AI Verdict
High-risk speculative hold/sell
Key drivers: Revenue collapse, Balance sheet strength, Overvaluation vs Intrinsic Value
Confidence
90%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Low Forward P/E
- Price near Graham Number
Watchpoints
- Price significantly above Intrinsic Value ($2.24)
- High PEG ratio (3.37)
Future
10/100
Ref Growth rates
Positives
- Low valuation floor
Watchpoints
- Revenue growth -95.30%
- Q/Q Revenue growth -95.34%
Past
20/100
Ref Historical trends
Positives
- Historical profitability in isolated quarters
Watchpoints
- Chronic earnings misses over 24 quarters
- Average surprise of -157.07% recently
Health
75/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Zero debt
- Massive cash cushion (Current Ratio 11.83)
Watchpoints
- Piotroski F-Score is only 4/9
- Operating losses are unsustainable
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.76
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SIGA and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SIGA
SIGA Technologies, Inc.
Primary
|
+2.3% | +19.3% | -0.8% | -35.2% | +10.7% | +9.2% |
|
KROS
Keros Therapeutics, Inc.
Peer
|
-80.9% | -70.2% | -8.5% | -28.6% | -0.6% | -6.6% |
|
CLLS
Cellectis S.A.
Peer
|
-83.4% | +71.4% | +189.7% | -12.0% | -6.7% | +6.0% |
|
LAB
Standard BioTools Inc.
Peer
|
-80.7% | -51.6% | -19.1% | -30.5% | -8.2% | -2.2% |
|
DCTH
Delcath Systems, Inc.
Peer
|
-28.7% | +68.5% | -11.4% | -10.5% | +6.0% | +4.2% |
SIG
SIGA Technologies, Inc.
Primary
5Y
+2.3%
3Y
+19.3%
1Y
-0.8%
6M
-35.2%
1M
+10.7%
1W
+9.2%
KRO
Keros Therapeutics, Inc.
Peer
5Y
-80.9%
3Y
-70.2%
1Y
-8.5%
6M
-28.6%
1M
-0.6%
1W
-6.6%
CLL
Cellectis S.A.
Peer
5Y
-83.4%
3Y
+71.4%
1Y
+189.7%
6M
-12.0%
1M
-6.7%
1W
+6.0%
LAB
Standard BioTools Inc.
Peer
5Y
-80.7%
3Y
-51.6%
1Y
-19.1%
6M
-30.5%
1M
-8.2%
1W
-2.2%
DCT
Delcath Systems, Inc.
Peer
5Y
-28.7%
3Y
+68.5%
1Y
-11.4%
6M
-10.5%
1M
+6.0%
1W
+4.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
14.88
Forward P/E
3.24
PEG Ratio
3.37
P/B Ratio
1.71
P/S Ratio
3.61
EV/Revenue
1.98
EV/EBITDA
7.7
Market Cap
$341.03M
Profitability
Profit margins and return metrics
Profit Margin
24.62%
Operating Margin
-250.38%
Gross Margin
47.49%
ROE
11.23%
ROA
6.39%
Growth
Revenue and earnings growth rates
Revenue Growth
-95.3%
Earnings Growth
N/A
Q/Q Revenue Growth
-95.34%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.0
Low debt
Current Ratio
11.83
Strong
Quick Ratio
8.79
Excellent
Cash/Share
$2.16
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
-111.7%
Op. Margin
-250.4%
Net Margin
-143.1%
Total Assets
$0.2B
Liabilities
$0.0B
Equity
$0.2B
Debt/Equity
0.10x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2014-03-10
$-0.08
-112.3% surprise
2013-11-06
$-0.09
-108.9% surprise
2013-08-05
$-0.06
-250.0% surprise
Healthcare Sector Comparison
Comparing SIGA against 447 companies in the Healthcare sector
(26 bullish, 140 neutral, 281 bearish)
P/E Ratio
14.88
This Stock
vs
87.83
Sector Avg
-83.1%
(Discount)
Return on Equity (ROE)
11.23%
This Stock
vs
-97.42%
Sector Avg
-111.5%
(Below Avg)
Profit Margin
24.62%
This Stock
vs
-14.95%
Sector Avg
-264.6%
(Weaker)
Debt to Equity
0.0
This Stock
vs
3.06
Sector Avg
-99.9%
(Less Debt)
Revenue Growth
-95.3%
This Stock
vs
147.85%
Sector Avg
-164.5%
(Slower)
Current Ratio
11.83
This Stock
vs
4.68
Sector Avg
+153.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SIGA
SIGA Technologies, Inc.
|
BEARISH | $341.03M | 14.88 | 11.2% | 24.6% | $4.76 | |
|
KROS
Keros Therapeutics, Inc.
|
NEUTRAL | $341.37M | 4.87 | 19.9% | 35.7% | $11.21 | Compare |
|
CLLS
Cellectis S.A.
|
BEARISH | $337.99M | - | -65.3% | -84.9% | $3.36 | Compare |
|
LAB
Standard BioTools Inc.
|
BEARISH | $345.33M | - | -13.1% | -87.8% | $0.89 | Compare |
|
DCTH
Delcath Systems, Inc.
|
NEUTRAL | $336.0M | 138.14 | 3.0% | 3.2% | $9.67 | Compare |
SIGA
SIGA Technologies, Inc.
BEARISH
Mkt Cap
$341M
P/E
14.9
ROE
11.2%
Price
$4.76
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-25 | MILLER LARRY R. | General Counsel | Stock Award | 6,920 | - |
| 2026-03-13 | NGUYEN DIEM | Chief Executive Officer | Stock Award | 85,045 | - |
| 2026-03-13 | MILLER LARRY R. | General Counsel | Stock Award | 21,261 | - |
| 2026-03-13 | HRUBY DENNIS E | Officer | Stock Award | 11,445 | - |
| 2026-03-13 | LUCKSHIRE DANIEL J | Chief Financial Officer | Stock Award | 11,503 | - |
| 2026-01-27 | NGUYEN DIEM | Chief Executive Officer | Stock Award | 55,902 | - |
MILLER LARRY R.
General Counsel
2026-03-25
6,920 shares
NGUYEN DIEM
Chief Executive Officer
2026-03-13
85,045 shares
MILLER LARRY R.
General Counsel
2026-03-13
21,261 shares
HRUBY DENNIS E
Officer
2026-03-13
11,445 shares
LUCKSHIRE DANIEL J
Chief Financial Officer
2026-03-13
11,503 shares
NGUYEN DIEM
Chief Executive Officer
2026-01-27
55,902 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
10-K
10-Q
8-K
10-Q
8-K
10-Q
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Past News Coverage
Recent headlines mentioning SIGA from our newsroom.
Newest → oldest
No matching news yet.